Pro Medicus Ltd logo

Pro Medicus Ltd

3
ASX:PME (Australia)   Ordinary Shares
A$ 114.82 (+1.92%) May 22
172.40
P/B:
75.35
Market Cap:
A$ 11.76B ($ 7.84B)
Enterprise V:
A$ 11.63B ($ 7.76B)
Volume:
238.09K
Avg Vol (2M):
269.52K
Also Trade In:
Volume:
238.09K
Avg Vol (2M):
269.52K
PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for Pro Medicus Ltd ( ASX:PME ) from 2000 to May 22 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Pro Medicus stock (ASX:PME) PE ratio as of May 22 2024 is 172.4. More Details

Pro Medicus Ltd (ASX:PME) PE Ratio (TTM) Chart

To

Pro Medicus Ltd (ASX:PME) PE Ratio (TTM) Historical Data

Total 1273
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 15
Pro Medicus PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2024-05-22 172.4 2024-03-20 144.2
2024-05-21 169.2 2024-03-19 145.8
2024-05-20 174.2 2024-03-18 149.3
2024-05-17 175.5 2024-03-15 146.1
2024-05-16 179.8 2024-03-14 149.3
2024-05-15 174.9 2024-03-13 150.5
2024-05-14 169.9 2024-03-12 149.4
2024-05-13 170.1 2024-03-11 148.8
2024-05-10 172.9 2024-03-08 152.0
2024-05-09 175.9 2024-03-07 147.7
2024-05-08 174.6 2024-03-06 149.4
2024-05-07 169.8 2024-03-05 150.8
2024-05-06 168.0 2024-03-04 149.7
2024-05-03 170.4 2024-03-01 155.2
2024-05-02 168.3 2024-02-29 155.9
2024-05-01 164.0 2024-02-28 153.2
2024-04-30 167.3 2024-02-27 150.0
2024-04-29 167.6 2024-02-26 149.2
2024-04-26 164.2 2024-02-23 147.5
2024-04-25 162.0 2024-02-22 141.9
2024-04-24 162.0 2024-02-21 139.6
2024-04-23 161.0 2024-02-20 142.4
2024-04-22 156.3 2024-02-19 131.5
2024-04-19 154.6 2024-02-16 131.0
2024-04-18 153.3 2024-02-15 141.1
2024-04-17 150.4 2024-02-14 162.3
2024-04-16 153.2 2024-02-13 161.9
2024-04-15 159.7 2024-02-12 167.2
2024-04-12 161.4 2024-02-09 160.3
2024-04-11 162.2 2024-02-08 160.5
2024-04-10 164.9 2024-02-07 161.1
2024-04-09 165.1 2024-02-06 162.6
2024-04-08 162.4 2024-02-05 163.1
2024-04-05 157.6 2024-02-02 157.4
2024-04-04 157.0 2024-02-01 151.1
2024-04-03 152.9 2024-01-31 152.5
2024-04-02 157.7 2024-01-30 151.9
2024-04-01 155.8 2024-01-29 151.6
2024-03-29 155.8 2024-01-26 150.3
2024-03-28 155.8 2024-01-25 150.3
2024-03-27 154.0 2024-01-24 151.2
2024-03-26 151.2 2024-01-23 151.8
2024-03-25 150.0 2024-01-22 150.5
2024-03-22 144.4 2024-01-19 149.7
2024-03-21 144.8 2024-01-18 145.1

Pro Medicus Ltd (ASX:PME) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Pro Medicus Ltd logo
Pro Medicus Ltd

ISIN : AU000000PME8

Share Class Description:

ASX:PME: Ordinary Shares
Description
Pro Medicus is a healthcare IT company specializing in radiology imaging software. Its main product, Visage 7, is a clinical desktop application that radiologists use to view, enhance, and manipulate images from any device and make a diagnosis. Its main customers are U.S. private academic hospitals. In fiscal 2022, Pro Medicus earned 79% of revenue in North America, 16% from Australia, and the remaining 6% in Europe.